Quality of life improvement with allergen immunotherapy treatment in patients with rhinoconjunctivitis in real life conditions. Results of an observational prospective study (ÍCARA)J. Cuesta-Herranz1, J.J. Laguna2, R. Mielgo3, I. Pérez-Camo4, A.M. Callejo5, L. Begoña email@example.com 6, M.C. Gomez6, B. Madariaga 6, A. Martinez6Show more: Authors information and Publication history
1IIS-Fundación Jiménez Díaz, Allergy Department, Madrid, Spain
2Allergy Unit, Allergo-Anaesthesia Unit, Hospital Central de la Cruz Roja, Faculty of Medicine, Alfonso X El Sabio University, ARADyAL, Madrid, Spain
3Hospital 12 de Octubre, Allergy Department, Madrid, Spain
4Hospital Royo Villanova, Allergy Department, Zaragoza, Spain
5Hospital Virgen de la Concha, Allergy Department, Zamora, Spain
6ROXALL Medicina España S.A., R and D Department, Zamudio, Bizkaia, Spain
Published online: 08 July 2019
Accepted: 14 June 2019
Received: 27 May 2019
Evaluate the changes in quality of life of patients with allergic rhinoconjunctivitis (AR), with or without asthma, after one-year treatment with allergen immunotherapy. Methods.
This was an observational prospective multicenter study. RQLQ questionnaire and VAS scale to assess treatment satisfaction were used. Impact on AR and asthma was also analyzed. Any adverse reaction was recorded. Results.
127 patients were recruited. Mean values in RQLQ decreased from 2.61 to 1.34 points, reflecting a statistically and clinically significant improvement (p < 0.01). The percentage of asthmatic patients decreased significantly (p < 0.01). Mean value of patients' satisfaction was 7.24 (SD = 1.90). Only 11 patients presented systemic reactions (9.17%), none of them serious. Conclusions.
One-year AIT treatment significantly increases QoL in patients with AR. Moreover, high patients' satisfaction values were reported, together with an adequate safety profile. Key words
allergic rhinoconjunctivitis; allergen immunotherapy; AIT; quality of life; HRQoL; RQLQ